| Biomarkers that correlate with active pulmonary tuberculosis treatment response: a systematic review and meta-analysis AJ Zimmer, F Lainati, N Aguilera Vasquez, C Chedid, S McGrath, ... Journal of clinical microbiology 60 (2), e01859-21, 2022 | 35 | 2022 |
| Association of baseline white blood cell counts with tuberculosis treatment outcome: a prospective multicentered cohort study C Chedid, E Kokhreidze, N Tukvadze, S Banu, MKM Uddin, S Biswas, ... International Journal of Infectious Diseases 100, 199-206, 2020 | 35 | 2020 |
| Multi-country evaluation of RISK6, a 6-gene blood transcriptomic signature, for tuberculosis diagnosis and treatment monitoring R Bayaa, MDB Ndiaye, C Chedid, E Kokhreidze, N Tukvadze, S Banu, ... Scientific Reports 11 (1), 13646, 2021 | 20 | 2021 |
| Relevance of QuantiFERON-TB gold plus and heparin-binding hemagglutinin interferon-γ release assays for monitoring of pulmonary tuberculosis clearance: a multicentered study C Chedid, E Kokhreidze, N Tukvadze, S Banu, MKM Uddin, S Biswas, ... Frontiers in immunology 11, 616450, 2021 | 13 | 2021 |
| In-depth immunophenotyping with mass cytometry during TB treatment reveals new T-cell subsets associated with culture conversion C Chedid, T Andrieu, E Kokhreidze, N Tukvadze, S Biswas, MF Ather, ... Frontiers in Immunology 13, 853572, 2022 | 6 | 2022 |
| Genetic diversity and characterization of M. tuberculosis isolates causing extrapulmonary tuberculosis in Bangladesh MKM Uddin, MF Ather, A Rahman, R Nasrin, SMM Rahman, S Kabir, ... Infection, Genetics and Evolution 95, 105052, 2021 | 6 | 2021 |
| Drug-resistant TB prevalence study in 5 health institutions in Haiti J Hoffmann, C Chedid, O Ocheretina, C Masetti, P Joseph, MM Mabou, ... Plos one 16 (3), e0248707, 2021 | 2 | 2021 |
| Relevance of QuantiFERON-TB Gold Plus and Heparin-Binding Hemagglutinin Interferon-g Release Assays for Monitoring of Pulmonary Tuberculosis Clearance: A Multicentered Study C Chedid, E Kokhreidze, N Tukvadze, S Banu, MKM Uddin, S Biswas, ... Immunological Biomarkers for Tuberculosis, 2022 | 1 | 2022 |
| Novel Immune Biomarkers for Pulmonary Tuberculosis Treatment Monitoring: a Multicentered study in Moderate-and High-Incidence Settings C Chedid Lyon, 2021 | | 2021 |
| Background: Tuberculosis (TB) is a leading infectious cause of death. To improve treatment efficacy, quicker monitoring methods are needed. The objective of this study was to … A Penn-Nicholson, EA Graviss, B Corleis, C Chedid, C Chedid, ... | | |
